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Abstract
Background: The incidence and prevalence of end-stage renal disease (ESRD) have
increased greatly in Canada over the last 2 decades. Because of the high cost of
therapy, predicting numbers of patients who will require dialysis and transplan-
tation is necessary for nephrologists and health care planners.
Methods: The authors projected ESRD incidence rates and therapy-specific preva-
lence by province to the year 2005 using 1981–1996 data obtained from the
Canadian Organ Replacement Register. The model incorporated Poisson regres-
sion to project incidence rates, and a Markov model for patient follow-up.
Results: Continued large increases in ESRD incidence and prevalence were pro-
jected, particularly among people with diabetes mellitus. As of Dec. 31, 1996,
there were 17 807 patients receiving renal replacement therapy in Canada. This
number was projected to climb to 32 952 by the end of 2005, for a relative in-
crease of 85% and a mean annual increase of 5.8%. The increased prevalence
was projected to be greatest for peritoneal dialysis (6.0% annually), followed by
hemodialysis (5.9%) and functioning kidney transplant (5.7%). The projected
annual increases in prevalence by province ranged from 4.4%, in Saskatch-
ewan, to 7.5%, in Alberta.
Interpretation: The projected increases are plausible when one considers that the in-
cidence of ESRD per million population in the United States and other countries
far exceeds that in Canada. The authors predict a continued and increasing short-
fall in resources to accommodate the expected increase in ESRD prevalence.
The incidence and prevalence of end-stage renal disease (ESRD) have in-creased greatly in Canada over the last 2 decades.1 Although relatively rare,ESRD is an important health problem because of the high cost of renal re-
placement therapy,2 the associated high mortality and the effect on patients’ quality
of life. Projecting future numbers of patients who will require dialysis and trans-
plantation is of interest to health care planners in order to forecast equipment, fa-
cility and other resource requirements. Previously, we provided ESRD prevalence
projections to the year 2000 at the national level.3 However, because the funding of
renal centres is a provincial responsibility, in this article we have projected ESRD
incidence rates and therapy-specific year-end prevalence by province to the year
2005, using enhanced methods previously described.4
Methods
Data were obtained from the Canadian Organ Replacement Register, a population-
based national organ failure registry of the Canadian Institute for Health Information.1
Data on demographic characteristics (e.g., date of birth, sex, province of residence, ethnic
background), comorbid conditions and underlying causes of renal failure (primary renal
diagnosis) are collected by each of the 86 renal centres from all patients at the start of
therapy. Clinical data (e.g., method of dialysis assigned and switches, transplantations and
transplant failures) are submitted annually. Deaths are reported along with the other fol-
low-up information.
Data were available for patients starting renal replacement therapy in Canada between
Jan. 1, 1981, and Dec. 31, 1996. For our analysis, we classified patients by age (≤ 44 years,
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45–64, ≥ 65) and primary renal diagnosis (diabetes mellitus sta-
tus). Population data were obtained from Statistics Canada.
The projection model we used has 2 components: incidence
and prevalence. Modelling was done separately for each province
to allow for differences in the parameters of the incidence and
prevalence components by province. Annual incidence rates were
projected for the years 1997 to 2005 based on extrapolations from
diabetes status-specific Poisson regression5 models fitted to the
1981–1996 data. Under the Poisson model, the logarithm (base e)
of the incidence rate is assumed to be a linear function of age and
year within each province/diabetes cross-classification. Separate
models for people with diabetes and those without diabetes were
fitted to allow the time trend to differ by both age and diabetes sta-
tus, while eliminating the potential need for third-order interac-
tion terms. Interaction and polynomial terms were included when
indicated. The relative goodness-of-fit of the models was com-
pared using the deviance.6 Variance estimates were appropriately
adjusted when evidence of under- or overdispersion was observed
(i.e., variability in the data was inconsistent with that of a Poisson
distribution).7 We computed 95% confidence intervals (CIs) for
the incidence projections using the large-sample normal approxi-
mation.6 As a supplementary analysis, prevalence projections to
2005 were produced, using the average annual incidence rate dur-
ing 1994–1996 instead of the Poisson-based incidence projections.
That is, the incidence rate was assumed to be constant between
1997 and 2005.
Follow-up was projected for 1997–2005 incident cases and
“currently prevalent” patients (i.e., patients receiving therapy as of
Dec. 31, 1996) using a Markov model.8 The Markov model con-
sists of a sequence of matrices, where each matrix contains inter-
state-transition probabilities pertaining to a specific follow-up 
interval. In this setting, the “states” included hemodialysis, peri-
toneal dialysis, functioning kidney transplant and death. The fa-
miliar survival model can be cast as a special case of the Markov
model with only 2 states (survival and death), and such a model
would have sufficed if our goal had been to project the total, as
opposed to the therapy-specific, number of prevalent ESRD 
patients. The Markov model permitted us to estimate therapy-
specific projections and thereby accommodated switches in thera-
peutic modality by patients.
Projected incident cases and currently prevalent cases were
multiplied by the appropriate sequence of transition matrices to
project the distribution of patients as time progressed. Therapy-
specific year-end prevalence by province was projected for
1997–2005 inclusive. A more detailed description and evaluation
of the projection model was the subject of a previous report.4
For internal validation of the projection model empirically, we
used 1981–1989 data to project year-end prevalence by province for
the years 1990–1996 using the methods described above. The pro-
jected and observed prevalence on Dec. 31, 1996, were compared.
Results
The demographic and basic clinical characteristics of the
34 710 ESRD patients who initiated renal replacement ther-
apy between Jan. 1, 1981, and Dec. 31, 1996, are presented in
Table 1. Diabetes was the underlying cause of renal failure
for 23.0% of the patients. The mean number of new patients
per year rose from 1366 during 1981–1985, to 1990 during
1986–1990 and to 2988 during 1991–1996. At the end of
1996, 41.7% of the registered patients receiving therapy were
receiving hemodialysis, 19.5% were receiving peritoneal dial-
ysis, and 38.9% had a functioning kidney transplant. Most of
the patients (39.5%) initiated therapy in Ontario.
The observed ESRD incidence rates per million popula-
tion by diabetes status and province during 1981–1996 are
listed in Table 2, along with the age-adjusted mean annual
relative increase. In each province the observed increase in
incidence was much more pronounced among people with
than among those without diabetes. Nationally, the age-
adjusted annual relative increase was estimated at 9.1%
among patients with diabetes and 4.1% among those with-
out diabetes. The relative increase was greatest in Mani-
toba and lowest in Ontario, irrespective of diabetes status.
The observed (1981 and 1996) and projected (2000 and
2005) incidence rates are listed by province in Table 3, along
with the age-adjusted mean annual observed and projected
increases. Manitoba had the highest observed incidence rate
in 1996 (143.8 per million population) and the highest 
projected relative increase (8.9%). The 95% CIs were 
narrowest for Ontario and widest for Manitoba. Clearly, 
precision decreased as the year increased, as evidenced by 
the wider CIs for 2005 than for 2000. In general the ordering
of provinces remained the same with respect to the observed
and projected rates. Nationally, the projected mean annual
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n = 34 710
17 928 (51.7)
(28.7)
Age at start of therapy, yr
(19.7)
(36.0)




No 26 718 (77.0)
Yes 7 992 (23.0)
Therapy status* n = 17 807
Hemodialysis 7 415
Table 1: Characteristics of Canadians with end-
stage renal disease (ESRD) who initiated renal
replacement therapy after Jan. 1, 1981
(41.6)
Peritoneal dialysis 3 467 (19.5)
Functioning kidney transplant 6 925 (38.9)
Vital status*
Alive 17 807 (51.3)
Dead 16 903 (48.7)
Province†
Atlantic provinces 3 438 (9.9)
Quebec 7 698 (22.2)
Ontario 13 714 (39.5)
Manitoba 1 800 (5.2)
Saskatchewan 1 344 (3.9)
Alberta 2 931 (8.4)
British Columbia 3 785 (10.9)
*As of Dec. 31, 1996.
†Province in which therapy was started.
increase in incidence was 5.5% during 1997–2005, compared
with 6.2% observed during 1981–1996.
The annual incidence rates for Canada by diabetes status
are displayed in Fig. 1. The increase in projected rates was
highest among patients 65 years of age and older, irrespec-
tive of diabetes status. Great increases were projected
among patients 45–64 with diabetes. Patients aged 44 and
less were projected to have stable incidence rates irrespec-
tive of diabetes status. In general the incidence trends pro-
jected for 1997–2005 were consistent with those observed
between 1981 and 1996.
The therapy-specific ESRD prevalence (number of pa-
tients at year end) by province during 1981–2005 is displayed
in Fig. 2, with summary data listed in Table 4. In general the
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Canada 49.5 111.2 6.2 154.2 (147.0–161.7) 214.5 (201.5–228.2) 5.5
Note: CI = confidence interval.





























































Canada 41.7 79.8 4.1 7.7 31.4 9.1
*Estimated using Poisson regression, adjusted for age (age and province, for Canada).
Fig. 1: Incidence rates (per million population) of end-stage renal disease (ESRD) in Canada during 1981–1996 (observed) and
1997–2005 (projected) among people without diabetes mellitus (left) and those with diabetes (right). Projected rates were ex-
trapolated from Poisson regression models fitted to 1981–1996 data.
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Hemodialysis               Peritoneal dialysis               Functioning transplant
Fig. 2: Therapy-specific prevalence of ESRD (year-end number of registered patients [initiated therapy after Jan. 1, 1981]) by
province during 1981–1996 (observed) and 1997–2005 (projected). Projections are based on a model that combined Poisson
regression for incidence rates and a Markov model for patient follow-up.
prevalence trends projected were consistent with the ob-
served prevalence. We projected that 32 952 patients will be
receiving renal replacement therapy by the end of 2005; of
these, 13 754 (41.7%) will be receiving hemodialysis, 6501
(19.7%) will be receiving peritoneal dialysis and 12 697
(38.5%) will have a functioning kidney transplant. The pro-
jected distribution by therapy for 2005 was virtually identical
to that observed in 1996 (41.6%, 19.5% and 38.9% respec-
tively). The mean annual increase in prevalence during
1997–2005 was projected to be highest in Manitoba (7.3%),
lowest in Saskatchewan (4.4%) and 5.8% nationally.
In the model in which the incidence rates of ESRD were
assumed to remain constant during 1997–2005, we pro-
jected that 25 065 patients in Canada will be receiving ther-
apy in 2005 (Table 5), an increase of 40.8% over the 1996
national prevalence.
To validate the accuracy of the projection model, we
used 1981–1989 data to project ESRD prevalence by
province to Dec. 31, 1996 (Table 6). The projected preva-
lence for 1996 differed from the observed prevalence by
1.3%. The relative error ranged from –2.3%, for Ontario,
to 10.4%, for British Columbia. Projected therapy-specific
counts closely approximated those observed in each
province (data not shown).
Interpretation
Our projected mean annual increase in ESRD preva-
lence of 5.8% during 1997–2005 would result in 32 952
Canadians requiring renal replacement therapy by the end
of 2005. This figure represents a relative increase of 85%
over the prevalence in 1996. The increase is cause for con-
cern because rationing of dialysis reportedly already occurs
in Canada, with several renal centres currently working be-
yond their actual capacity.9–11
The validity of our projection model is supported from a
methodological perspective. With respect to incidence,
Poisson regression is frequently used for rate modelling,6
and the Poisson model has a long history of being used in
the modelling of rare events such as ESRD incidence.6,8 Re-
garding patient follow-up, the Markov model has been suc-
cessfully used previously in the context of ESRD plan-
ning12–14 and is naturally suited to this setting.
In general our projected incidence and prevalence
trends were consistent with the observed trends. That the
rates of therapy initiation could further increase beyond
current levels is supported by the fact that, despite the large
increases already experienced in Canada, incidence rates
are much higher in the United States and other developed
countries such as Germany and Japan.15–17 A potential liabil-
ity is the assumption of exponential increase in incidence
over time. The observed trends were indeed exponential,
consistent with trends in other countries.18,19 Although ex-
ponential trends may not persist for extended periods, the
practical value of the Poisson model for incidence projec-
tions has been previously demonstrated.20
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British Columbia 793 336 945 2 074
Canada 7 415 3 467 6 925 17 807
Projected (2005)*
Atlantic provinces 1 020 (6.0) 849 (6.9) 1 347 (5.6) 3 216 (6.0)
Quebec 3 405 (5.9) 1 402 (6.5) 2 427 (5.3) 7 235 (5.8)
Ontario 5 149 (5.0) 2 538 (5.2) 4 655 (5.5) 12 342 (5.2)
Manitoba 1 039 (8.9) 280 (7.3) 478 (4.4) 1 796 (7.3)
Saskatchewan 426 (4.9) 157 (4.0) 329 (4.0) 911 (4.4)
Alberta 1 344 (8.3) 689 (7.8) 1 498 (6.7) 3 532 (7.5)
British Columbia 1 372 (5.1) 586 (5.2) 1 963 (7.1) 3 921 (6.1)
Canada 13 754 (5.9) 6 501 (6.0) 12 697 (5.7) 32 952 (5.8)
*Projections are based on a model that combined the Poisson model for incidence and a Markov model of patient follow-up. The
sum of the numbers may not equal row and column totals because of rounding.
In terms of reconciling the increase in ESRD incidence,
the issue of competing mortality has been raised21 and ap-
plies to Canada and other developed areas of the world.
That is, patients with coronary artery disease, which has
risk factors common to ESRD (e.g., hypertension), are sur-
viving longer because of vast improvements in treatment,
and therefore they are at higher risk for ESRD. Increased
diabetes prevalence is a hypothesized explanation for the
rise in ESRD incidence in Canada and other countries.22–24
Our findings indicated that the increase in ESRD incidence
was more pronounced among patients with than among
those without diabetes. Because reliable estimates of dia-
betes incidence or prevalence are unavailable, we cannot
tell whether the prevalence of diabetes is increasing, or
whether ESRD incidence is increasing in a perhaps con-
stant population of people with diabetes. It is also possible
that the proportion of diabetic patients with ESRD who
are referred for therapy has increased.
The projection model’s internal validity was demon-
strated by the fact that the model using 1981–1989 data
projected the prevalence during 1990–1996 adequately.
Naturally, such “data–splitting” procedures understate the
accuracy of the full-data model. That is, in the validation
model, data for only 9 years were used, with the projected
time span equal to 78% (7/9) of the time span of the data.
In the main model, data for 16 years were available, with a
projected time span equal to 56% (9/16) of the data’s time
span. Furthermore, for diseases such as ESRD, which have
a high death rate, prevalence projections are very sensitive
to the specified incidence model. This sensitivity increases
greatly, as does the instability of the incidence model, as
the number of available data points decreases.
The projected therapy-specific prevalence of ESRD
was considerably lower when we assumed that the inci-
dence would remain constant over time. The purpose of
this model was to assess the impact of a plateau at current
incidence rates. If the observed increase in therapy were
due to increased acceptance of therapy, and all ESRD pa-
tients were indeed referred for treatment, then we would
expect incidence to level off at current rates. There was
evidence of plateauing in the age group most likely to be
referred to a nephrologist (those 44 years of age and
younger). However, we found no evidence of plateauing
in the 2 groups currently generating the greatest number
of new cases: patients aged 65 and older, and diabetic pa-
tients aged 45–64. In the United States the number of pa-
tients receiving renal replacement therapy per million
population (949 in 199415) greatly exceeds that in Canada,
even after adjustment for race. There is no evidence yet of
a plateau, even though predictions from the 1970s were
that a plateau would occur in the 1980s.18 Even if inci-
dence rates were to remain constant, the projected in-
crease of 40.8% in prevalence for 2005 is still sizeable,
particularly for an already overburdened health care sys-
tem. As well, the annual number of new cases per year
would still increase, despite constant incidence rates, be-
cause continued population increases are projected, par-
ticularly of elderly people.
Our study has some limitations. Because we lacked data
on the true underlying incidence and prevalence of
ESRD, we could not estimate the proportion of patients
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Canada 9 492 4 192 11 381 25 065
*The incidence rate of ESRD observed between 1994–1996 was assumed to remain constant between 1997 and 2005.
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Canada 17 807 17 572 –235 –1.3
*Calculated using 1981–1989 data. Projections are based on a model that combined Poisson
regression for incidence and a Markov model of patient follow-up.
†Difference between projected and observed numbers.
‡(projected – observed)/observed × 100%.
receiving renal replacement therapy among those requir-
ing treatment. As well, data were only available for regis-
tered patients (i.e., those who initiated therapy after
Jan. 1, 1981). This would result in the ESRD prevalence
in 2005 being underestimated to the degree that nonreg-
istered patients survive and would primarily affect the
number of patients undergoing transplantation. Our pro-
jections are limited by the contingency of their validity on
the persistence of observed trends, a limitation inherent
in forecasting.
The large projected increase in the number of ESRD
cases has serious implications for Canada’s health care sys-
tem. The predicted rise in prevalence indicates that there
will be a substantial burden on health care resources and on
patients’ health. We therefore urge social and health care
planners to consider projections of ESRD rates in their
planning of future services.
We thank the Canadian Organ Replacement Register for pro-
viding the data.
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